About Keratin, type I cytoskeletal 19
Keratin, type I cytoskeletal 19 (KRT19) is a protein
from Homo sapiens identified by UniProt accession
P08727, 400 residues long.
MolForge cross-references it against 0 known binders and
595 disease associations.
Target properties
| Protein name | Keratin, type I cytoskeletal 19 |
| UniProt accession | P08727 |
| Gene | KRT19 |
| Organism | Homo sapiens |
| Length | 400 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (595)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.19
- glioblastoma multiforme · score 0.19
- clear cell renal carcinoma · score 0.19
- breast adenocarcinoma · score 0.18
- esophageal cancer · score 0.14
- hepatocellular carcinoma · score 0.13
- hereditary breast ovarian cancer syndrome · score 0.12
- Hereditary breast and ovarian cancer syndrome · score 0.12
- neoplasm · score 0.12
- papillary thyroid carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P08727-F1 | alphafold | PREDICTED | 79.91 | — |
Amino-acid sequence (400 residues)
MTSYSYRQSS ATSSFGGLGG GSVRFGPGVA FRAPSIHGGS GGRGVSVSSA RFVSSSSSGA YGGGYGGVLT ASDGLLAGNE KLTMQNLNDR LASYLDKVRA LEAANGELEV KIRDWYQKQG PGPSRDYSHY YTTIQDLRDK ILGATIENSR IVLQIDNARL AADDFRTKFE TEQALRMSVE ADINGLRRVL DELTLARTDL EMQIEGLKEE LAYLKKNHEE EISTLRGQVG GQVSVEVDSA PGTDLAKILS DMRSQYEVMA EQNRKDAEAW FTSRTEELNR EVAGHTEQLQ MSRSEVTDLR RTLQGLEIEL QSQLSMKAAL EDTLAETEAR FGAQLAHIQA LISGIEAQLG DVRADSERQN QEYQRLMDIK SRLEQEIATY RSLLEGQEDH YNNLSASKVL
Explore Keratin, type I cytoskeletal 19 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets